Tirzepatide is a dual incretin agonist measured for islet function, insulin sensitivity, and weight — here is what the trials recorded.

TL;DR

Tirzepatide is a prescription medicine approved by the FDA in 2022 for type 2 diabetes and in 2023 for obesity. It is a synthetic peptide — 39 amino acids long — that activates two receptors at once: the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor (glucagon-like peptide-1). Both are gut hormones that help the body manage blood sugar after meals. By hitting both simultaneously, tirzepatide pushes harder on insulin release, glucose control, and appetite than either signal alone. Clinical trials called SURPASS (for type 2 diabetes) and SURMOUNT (for obesity) enrolled tens of thousands of participants and measured the outcomes. The headline number for obesity: a mean body-weight reduction of 20.9% at the highest dose in 72 weeks, versus 3.1% with placebo ^[4]. The headline for blood sugar: HbA1c fell 2.30 percentage points at 15 mg, outperforming a leading comparator by about half a point ^[3]. What people report — appetite suppression, energy changes, GI side effects, and a few things to watch for — is covered on the Tirzepatide effects page.

What the trials measured

Tirzepatide's phase 3 record is one of the largest for any incretin-class drug. The SURPASS programme covered type 2 diabetes — five trials plus a cardiovascular outcomes study, thousands of participants, comparators including basal insulin and other glucose-lowering agents. The SURMOUNT programme covered obesity and overweight. Key outputs:

Glycaemic control (SURPASS-2, n=1,879, 40 weeks): tirzepatide 5/10/15 mg reduced HbA1c (glycated haemoglobin — a 3-month average blood-glucose marker) by 2.01/2.24/2.30 percentage points versus 1.86 with the comparator ^[3]. Tirzepatide was non-inferior and superior at all three doses.

Weight (SURMOUNT-1, n=2,539, 72 weeks): mean weight change -15.0% at 5 mg, -19.5% at 10 mg, -20.9% at 15 mg, versus -3.1% with placebo ^[4].

Head-to-head on weight (SURMOUNT-5, n=751, 72 weeks): -20.2% tirzepatide versus -13.7% with a leading comparator dose (P<0.001) ^[5].

Beta-cell and insulin-sensitivity (Heise 2022, n=117, 28 weeks): tirzepatide 15 mg increased the clamp disposition index — a combined measure of insulin secretion and insulin sensitivity — by an estimated treatment difference of 1.92 versus placebo (95% CI 1.59-2.24; P<0.0001) and by an ETD of 0.84 versus the comparator (95% CI 0.46-1.21) ^[8]. It also improved the M-value (insulin sensitivity from the clamp) by an ETD of 1.52 mg/min/kg and the insulin secretion rate by an ETD of 102.09 pmol/min/m² versus the comparator ^[8].

The lens for this site is the islet-function and insulin-sensitivity story. Explore the tirzepatide mechanism of action for the full mechanistic read, the Tirzepatide research page for the broader trial record, and the Tirzepatide effects page for what the community reports.

Tirzepatide peptide structure

Tirzepatide is a Tirzepatide peptide: a linear 39-amino-acid synthetic molecule built on the native GIP hormone backbone, modified with a C20 fatty diacid arm (eicosanedioic acid) attached via a glutamic acid linker and two AEEA spacer units to a lysine side chain. Molecular weight: 4,813.53 Da. Molecular formula: C225H348N48O68. ATC code: A10BX16. CAS: 2023788-19-2 ^[1].

The fatty-diacid arm binds albumin in plasma with high affinity, extending the effective half-life to approximately five days and enabling once-weekly subcutaneous dosing ^[1]. This pharmacokinetic design is the basis for the once-weekly schedule observed across the entire SURPASS and SURMOUNT programme ^[8].

The peptide is not endogenous. It is a synthetic engineer of the incretin system — not extracted from any tissue, not a replication of a naturally occurring molecule.

Regulatory status

FDA approval record for tirzepatide:

• May 2022: approved for adults with type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise ^[12].
• November 2023: approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition ^[12].
• Subsequently: approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity ^[12].

The prescribing information carries a boxed warning regarding the risk of thyroid C-cell tumours observed in rodent studies. The label contraindicates tirzepatide in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[12].

This site does not dispense, prescribe, or sell tirzepatide. This is an independent editorial digest of the published clinical-trial and peer-reviewed literature on the compound.

Tirzepatide results at a glance

Tirzepatide results across major trials ^{[3][4][5][8][11]}:

| Endpoint | Dose | Result | |---|---|---| | HbA1c change (SURPASS-2, 40 wk) | 15 mg | -2.30 pp | | Body weight change (SURMOUNT-1, 72 wk) | 15 mg | -20.9% | | Body weight vs comparator (SURMOUNT-5, 72 wk) | 15 mg max | -20.2% vs -13.7% | | Clamp disposition index ETD (Heise 2022, 28 wk) | 15 mg | +1.92 vs placebo | | M-value ETD vs comparator (Heise 2022) | 15 mg | +1.52 mg/min/kg | | HbA1c best incretin (38-RCT network, Kang 2025) | 15 mg | -1.79% largest reduction |

All figures are from cited randomised controlled trials. Context for each, including sample sizes, duration, and comparator arms, is on the Tirzepatide research page.